The past decade has been a bad one for antidepressant manufacturers.
Quite apart from all the bad press these drugs have been getting lately, there's been a remarkable lack of new antidepressants making it to the market. The only really novel drugs to hit the shelves since 2000 have been agomelatine and vilazodone. There were a couple of others that were just minor variants on old molecules, but that's it. Quite a contrast from the 1990s when new drugs were ten-a-penny.
